Serum beta 2 microglobulin levels help assess hematologic neoplasia activity and tumor burden. Elevated levels indicate active disease, particularly in multiple myeloma and lymphoma, aiding in monitoring treatment response.
Area of Science:
Clinical Chemistry
Hematology
Oncology
Background:
Beta 2 microglobulin (B2M) is a low molecular weight protein associated with HLA antigens.
Elevated serum B2M levels are observed in various cancers and renal failure.
Purpose of the Study:
To determine plasma and spinal fluid B2M concentrations in healthy individuals and patients with hematologic neoplasia.
To evaluate the utility of B2M as a biomarker for disease activity and tumor mass in hematologic malignancies.
Main Methods:
Radioimmunoassay (RIA) was used to measure B2M concentrations.
Study included 57 healthy individuals and patients with multiple myeloma, non-Hodgkin lymphoma, and acute lymphatic leukemia.
Main Results:
Healthy subjects had serum B2M of 1.34 +/- 0.34 mg/l and spinal fluid levels of 1.3 +/- 0.7 mg/l.
Multiple myeloma patients showed significantly higher serum B2M (7.51 mg/l), especially with renal failure (12.35 mg/l).
Non-Hodgkin lymphoma patients had elevated B2M (2.90 mg/l), correlating with active disease (3.18 mg/l) versus remission (1.5 mg/l).
Acute lymphatic leukemia patients exhibited elevated B2M during active disease (3.37 mg/l), normalizing post-remission (1.79 mg/l).
Elevated spinal fluid B2M was specific to central nervous system involvement.
Conclusions:
Serum B2M levels are valuable for assessing disease activity and tumor burden in hematologic neoplasias.
B2M is particularly useful in monitoring multiple myeloma and lymphoma, reflecting disease status and response to therapy.
